19945-78-9

Upstream product

• 1824-96-0 methyl ribofuranoside 
• 532-20-7 D-Ribose 
• 98-88-4 benzoyl chloride 
• 13039-68-4 methyl 5-O-p-tosyl-D-ribofuranoside 
• 98-59-9 p-toluenesulfonyl chloride 
• 7473-45-2 1-O-methyl-D-ribofuranose 
• 35452-26-7 methyl 5-O-toluenesulfonyl-β-D-ribofuranoside 

Downstream Products

• 267662-02-2 methyl-5-deoxy-5-trifluoroacetylamino-2,3-di-O-benzoyl-β-D-ribofuranoside 
• 267661-99-4 1-O-acetyl-5-acetylamino-2,3-di-O-benzoyl-5-deoxy-α,β-D-ribofuranose 
• 267662-01-1 C₂₂H₂₃NO₇ 
• 174175-00-9 methyl 5-azido-2,3-di-O-benzoyl-5-deoxy-β-D-ribofuranoside 

Relevant academic research and scientific papers

Phosphorylated Glycoconjugates Based on Isosteviol, d-Arabinofuranose, and d-Ribofuranose

First phosphorylated glycoconjugates were synthesized in three stages on the basis of isosteviol, d-arabinofuranose, and d-ribofuranose. In the first stage, isosteviol reacted with methyl 5-O-(p-tosyl)-2,3-di-O-benzoyl-d-ribofuranoside and methyl 5-O-(p-tosyl)-2,3-di-O-benzoyl-d-arabinofuranoside to give glycoconjugates in which the diterpenoid fragment is linked through ester bond to the carbohydrate C5 atom. In the second stage, the anomeric methoxy group in the furanoside fragment was replaced by bromine, and the resulting 2,3-di-O-benzoyl-d-ribofuranosyl and 2,3-di-O-benzoyl-d-arabinofuranosyl bromides were treated with dibutyl phosphate to afford the target phosphorylated derivatives.

Synthesis and in vitro investigation of potential antiproliferative monosaccharide–D-secoestrone bioconjugates

The syntheses of monosaccharide–D-secoestrone conjugates are reported. They were prepared from 3-(prop-2-inyloxy)-D-secoestrone alcohol or oxime and monosaccharide azides via Cu(I)-catalyzed azide–alkyne cycloaddition reactions (CuAAC). The antiproliferat

Synthesis of biomimetic analogs of neomycin B: Potential inhibitors of the HIV RNA Rev response element

The aminoglycosidic antibiotic, neomycin B, is an inhibitor of the binding of Rev to RRE. This paper reports on the synthesis of analogs of neomycin B as potential anti-HIV compounds designed to function as inhibitors of Rev/RRE binding.